These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35914546)

  • 21. Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach.
    Garçon N; Morel S; Didierlaurent A; Descamps D; Wettendorff M; Van Mechelen M
    BioDrugs; 2011 Aug; 25(4):217-26. PubMed ID: 21815697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Next generation polyphosphazene immunoadjuvant: Synthesis, self-assembly and in vivo potency with human papillomavirus VLPs-based vaccine.
    Marin A; Chowdhury A; Valencia SM; Zacharia A; Kirnbauer R; Roden RBS; Pinto LA; Shoemaker RH; Marshall JD; Andrianov AK
    Nanomedicine; 2021 Apr; 33():102359. PubMed ID: 33476764
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9-14 years: Results to month 36 from a randomized trial.
    Leung TF; Liu AP; Lim FS; Thollot F; Oh HML; Lee BW; Rombo L; Tan NC; Rouzier R; De Simoni S; Suryakiran P; Hezareh M; Thomas F; Folschweiller N; Struyf F
    Vaccine; 2018 Jan; 36(1):98-106. PubMed ID: 29174109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Altered antigenicity and immunogenicity of human papillomavirus virus-like particles in the presence of thimerosal.
    Chen S; Huang X; Li Y; Wang X; Pan H; Lin Z; Zheng Q; Li S; Zhang J; Xia N; Zhao Q
    Eur J Pharm Biopharm; 2019 Aug; 141():221-231. PubMed ID: 31154067
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice.
    Han JE; Wui SR; Park SA; Lee NG; Kim KS; Cho YJ; Kim HJ; Kim HJ
    Vaccine; 2012 Jun; 30(28):4127-34. PubMed ID: 22561312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of a highly thermostable, adjuvanted human papillomavirus vaccine.
    Hassett KJ; Meinerz NM; Semmelmann F; Cousins MC; Garcea RL; Randolph TW
    Eur J Pharm Biopharm; 2015 Aug; 94():220-8. PubMed ID: 25998700
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial.
    Einstein MH; Takacs P; Chatterjee A; Sperling RS; Chakhtoura N; Blatter MM; Lalezari J; David MP; Lin L; Struyf F; Dubin G;
    Hum Vaccin Immunother; 2014; 10(12):3435-45. PubMed ID: 25483701
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimized dose of synthetic analogues of Monophosphoryl lipid A as an effective alternative for formulating recombinant human papillomavirus vaccine.
    Azimi A; Heidarian S; Zamani H; Taleghani N; Dehghani M; Seyedjafari E
    Biologicals; 2020 Nov; 68():60-64. PubMed ID: 32859464
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimization and validation of ELISA immunoassay for the evaluation of in-vitro relative potency of a four-component human papillomavirus vaccine products.
    Mostafa MM; Al-Ghobashy MA; Fathalla FA; Salem MY
    Biologicals; 2016 Nov; 44(6):596-599. PubMed ID: 27522938
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluating the Compatibility of New Recombinant Protein Antigens (Trivalent NRRV) with a Mock Pentavalent Combination Vaccine Containing Whole-Cell Pertussis: Analytical and Formulation Challenges.
    Kumar P; Holland DA; Secrist K; Taskar P; Dotson B; Saleh-Birdjandi S; Adewunmi Y; Doering J; Mantis NJ; Volkin DB; Joshi SB
    Vaccines (Basel); 2024 Jun; 12(6):. PubMed ID: 38932338
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single-stranded RNA adjuvant enhances the efficacy of 10-valent human papilloma virus-like particle vaccine.
    Kwak HW; Shin W; Baik K; Kim M; Park Y; Hong SH; Park HJ; Park HJ; Bang YJ; Kim JY; Lee YS; Kim IB; Kim HL; Kim H; Nam JH
    Microbiol Immunol; 2022 Nov; 66(11):529-537. PubMed ID: 35979884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15-25 Years.
    Puthanakit T; Huang LM; Chiu CH; Tang RB; Schwarz TF; Esposito S; Frenette L; Giaquinto C; McNeil S; Rheault P; Durando P; Horn M; Klar M; Poncelet S; De Simoni S; Friel D; De Muynck B; Suryakiran PV; Hezareh M; Descamps D; Thomas F; Struyf F
    J Infect Dis; 2016 Aug; 214(4):525-36. PubMed ID: 26908726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials.
    Mariz FC; Gray P; Bender N; Eriksson T; Kann H; Apter D; Paavonen J; Pajunen E; Prager KM; Sehr P; Surcel HM; Waterboer T; Müller M; Pawlita M; Lehtinen M
    Lancet Infect Dis; 2021 Oct; 21(10):1458-1468. PubMed ID: 34081923
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunoaffinity extraction using conformation-dependent antibodies coupled to SE-HPLC for the development of stability and potency-indicating assay for quadrivalent human papillomavirus vaccine.
    Mostafa MM; Al-Ghobashy MA; Fathalla FA; Salem MY
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Oct; 1032():211-217. PubMed ID: 27037127
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sustained Cross-reactive Antibody Responses After Human Papillomavirus Vaccinations: Up to 12 Years Follow-up in the Finnish Maternity Cohort.
    Kann H; Lehtinen M; Eriksson T; Surcel HM; Dillner J; Faust H
    J Infect Dis; 2021 Jun; 223(11):1992-2000. PubMed ID: 33009576
    [TBL] [Abstract][Full Text] [Related]  

  • 36. N-terminal truncations on L1 proteins of human papillomaviruses promote their soluble expression in Escherichia coli and self-assembly in vitro.
    Wei M; Wang D; Li Z; Song S; Kong X; Mo X; Yang Y; He M; Li Z; Huang B; Lin Z; Pan H; Zheng Q; Yu H; Gu Y; Zhang J; Li S; Xia N
    Emerg Microbes Infect; 2018 Sep; 7(1):160. PubMed ID: 30254257
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine.
    Rowhani-Rahbar A; Alvarez FB; Bryan JT; Hughes JP; Hawes SE; Weiss NS; Koutsky LA
    J Clin Virol; 2012 Mar; 53(3):239-43. PubMed ID: 22209292
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study.
    Romanowski B; Schwarz TF; Ferguson LM; Peters K; Dionne M; Schulze K; Ramjattan B; Hillemanns P; Catteau G; Dobbelaere K; Schuind A; Descamps D
    Hum Vaccin; 2011 Dec; 7(12):1374-86. PubMed ID: 22048171
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes.
    Godi A; Boampong D; Elegunde B; Panwar K; Fleury M; Li S; Zhao Q; Xia N; Christensen ND; Beddows S
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32967963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Head-to-Head Comparison of Bi- and Nonavalent Human Papillomavirus Vaccine-Induced Antibody Responses.
    Arroyo Mühr LS; Eklund C; Lagheden C; Eriksson T; Pimenoff VN; Gray P; Lehtinen M; Dillner J
    J Infect Dis; 2022 Sep; 226(7):1195-1199. PubMed ID: 35535025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.